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Blood coagulation factor XIII (FXIII) cross-links ﬁbrin on
activation (i.e. cleavage) by thrombin to stabilize a ﬁbrin clot.
The common Val34Leu mutation in the FXIII A subunit is
located only three amino acids from the thrombin cleavage site,
and could thus potentially alter the clot-stabilizing propensity
of FXIII. Previously, it has been shown that thrombin activates
FXIII 34Leu more rapidly and at lower concentration than
34Val [1,2]. Early activation of FXIII leads to early cross-
linking of ﬁbrin, which seems to inhibit lateral aggregation of
the ﬁbrin ﬁbres, and renders the ﬁbrin clot less porous and
made up of thinner ﬁbers than a clot cross-linked by 34Val.
Plasma clots consisting of thin ﬁbrin ﬁbers are relatively
resistant to plasma degradation [3]; however, studies which
determined the risk of venous thrombosis of carriers relative to
non-carriers reported either a protective eﬀect or no eﬀect of
the FXIII Val34Leu mutation on the risk of venous disease
[4–8]. In the LETS study, carriers of the 34Leu allele showed
higher FXIII activity, but no higher FXIII subunit levels. At
most a weak protective eﬀect for venous thrombosis was found
for the 34Leu allele (OR 0.9; 95% CI 0.7–1.1), which was
completely restricted to men, with a higher protective eﬀect in
homozygotes (OR 0.7; 95% CI 0.4–1.3) [9].
High ﬁbrinogen levels lead, like the factor 34Leu variant, to
a less porous and therefore less permeable ﬁbrin clot with thin
ﬁbres, which is associated with an increased risk of myocardial
infarction and premature coronary artery disease [10,11]. These
effects seem contradictory, however, as Lim et al. [12] found
that 34Leu homozygous patients form ﬁbrin clots with lower
permeability than 34Val homozygotes at low ﬁbrinogen
concentrations, but that the permeability was similar for both
genotypes at intermediate ﬁbrinogen levels and even higher for
the 34Leu homozygotes at high ﬁbrinogen levels. This would
predict a protective effect of 34Leu at high ﬁbrinogen levels.
Therefore, we decided to determine the inﬂuence of ﬁbrinogen
levels on the effect of the FXIII Val34Leu mutation on venous
thrombotic risk.
This studywas performed using plasma samples from a large
population-based case–control study on risk factors for venous
thrombosis, the Leiden Thrombophilia Study (LETS) [13]. In
this study, 474 consecutive patients with an objectively diag-
nosed ﬁrst episode of deep venous thrombosis and 474 age- and
Correspondence: Professor F. R. Rosendaal MD, Department of
Clinical Epidemiology, Leiden University Medical Center, PO Box
9600, 2300 RC Leiden, the Netherlands.
Tel.: +31 71 526 4037; fax: +31 526 6994; e-mail:2 F.R.Rosendaal@
lumc.nl
Received 17 January 2005, accepted 25 January 2005
1102 Letters to the Editor
 2005 International Society on Thrombosis and Haemostasis
sex-matched friends or partners of these patients were included.
For this analysis, we included all patients and controls tested for
the FXIII Val34Leu variant (genotype informationwasmissing
for three patients). FXIII Val34Leu genotyping was performed
using an allele-speciﬁc polymerase chain reaction as described
previously [9,14]. Fibrinogen levels were measured with the
Clauss method using Dade thrombin (Baxter, Miami, FL,
USA). We calculated odds ratios (ORs) and 95% conﬁdence
intervals (CI) for venous thrombosis associated with the 34Leu
variant for those with high and normal levels of ﬁbrinogen
(using a 90th percentile cut-off point).
The mean age at the time of the blood draw was 45 years in
the patients and the controls (range patients 15–68, range
controls 15–71). Of the patients, 202 (43%)weremen compared
with 202 controls (43%). The allele frequency of the Val34Leu
mutation was 0.20 in the 471 patients (165 carriers; 20 were
homozygous) and 0.24 in the 474 controls (201 carriers; 27
homozygotes).Themeanﬁbrinogen levelswere3.4 g L)1 (range
1.5–8.0) for cases and 3.3 g L)1 (range 1.7–6.3) for controls.
Table 1 shows the odds ratios for venous thrombosis for the
Val34Leu variant stratiﬁed by normal (below the 90th
percentile) or high (above the 90th percentile) levels of
ﬁbrinogen. The 34Leu variant does not confer a protective
effect in heterozygote carriers of the 34Leu variant with normal
ﬁbrinogen levels, either overall or in men or women separately.
In homozygote 34Leu carriers with normal ﬁbrinogen levels we
did ﬁnd a protective effect, especially inmen. A protective effect
of 34Leu was present for individuals with high ﬁbrinogen
levels, again particularly for men (Table 1).
Earlier we found in the LETS that the risk of venous
thrombosis associated with high levels of ﬁbrinogen was
increased mainly in individuals older than 45 years [15].
Stratiﬁcation by age in the current analysis (below and above
45 years) did not change the ORs at normal ﬁbrinogen levels in
carriers, heterozygotes and homozygotes for the 34Leu variant
(OR was 0.9 for those below and above the age of 45 years).
However, at high ﬁbrinogen levels the OR in carriers was 0.8
(95% CI 0.2–3.0) below 45 years old and 0.4 (95% CI 0.2–1.0)
above 45 years old.
Our ﬁndings show clinical evidence for the observations of
Lim et al. [12] suggesting that the protective effect of the 34Leu
variant at high ﬁbrinogen levels may be accounted for by the
formation of more permeable ﬁbrin clots at high ﬁbrinogen
concentrations than at low ﬁbrinogen concentrations.
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Table 1 Risk of venous thrombosis associated with the FXIII 34Leu
mutation according to ﬁbrinogen levels
Fibrinogen
levels FXIII OR* overall OR men OR women
Normal
(< ¼ 4.11)
Val34Leu 1.0 (0.7–1.3) 0.9 (0.6–1.4) 1.0 (0.7–1.5)
Leu34Leu 0.6 (0.3–1.2) 0.4 (0.1–1.4) 0.8 (0.3–1.9)
Val34Leu/
Leu34Leu
0.9 (0.7–1.2) 0.8 (0.5–1.3) 1.0 (0.7–1.4)
High
(> 4.11)
Val34Leu 0.4 (0.2–0.9) 0.2 (0.1–0.7) 0.7 (0.3–1.9)
Leu34Leu 0.7 (0.2–3.1) 0.2 (0.0–2.1) 1.8 (0.2–18.4)
Val34Leu/
Leu34Leu
0.5 (0.2–1.0) 0.2 (0.1–0.7) 0.8 (0.3–2.1)
*Risks are calculated with individuals carrying Val34Val as reference
group.
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